Melanotan II vs PT-141: A Research Comparison (2026)

Melanotan II and PT-141 are the rare case where one research compound is literally derived from the other. PT-141 is melanotan II's active metabolite — the piece that researchers noticed was doing something in the brain rather than the skin, then carved out into its own program. Studying them side by side is instructive precisely because they share so much chemistry yet diverge so completely in selectivity, status, and how each must be verified. This comparison maps that split, strictly for laboratory research use.

Framing up front: Both are research compounds here. The approved drug bremelanotide is a separate, regulated pharmaceutical — not the research-grade PT-141 sold by chemical suppliers — and melanotan II is not approved at all. Nothing below is human-use, cosmetic, or therapeutic guidance, and no outcomes are claimed. Research-compound material is not for human consumption.

Parent and metabolite

The relationship is the starting point. Melanotan II (MT-2) is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH), engineered at the University of Arizona in the 1990s as a stable tool for pigmentation research. During its characterization, researchers observed that a melanotan-II metabolite produced central, arousal-related effects unrelated to skin pigment — and that metabolite became PT-141 (bremelanotide).

Property	Melanotan II	PT-141 (bremelanotide)
Relationship	Parent compound	Active metabolite
Structure	Cyclic heptapeptide	Cyclic heptapeptide
Approx. molecular weight	~1024 Da	~1025 Da
Receptor profile	Non-selective (MC1R–MC5R)	Shifted toward central MC4R
Regulatory status (US)	Not approved (research only)	FDA-approved as Vyleesi; research-grade is research-only

Both are cyclic — the backbone closed into a ring, which boosts stability and receptor-binding fit relative to native α-MSH. The ring is not where they differ. The difference is in which receptors each one pulls on, and how hard. Our melanotan II research profile and PT-141 research profile cover each compound on its own terms; this piece is the head-to-head.

Selectivity: the defining contrast

The single most important difference is selectivity, and it runs in PT-141's favor as a focused research tool.

Melanotan II is a broad, non-selective melanocortin agonist. It activates across the receptor family — MC1R through MC5R — with strong MC1R activity driving the melanogenesis it was designed to study, and meaningful MC4R activity producing central effects beyond pigmentation. That breadth is exactly what makes it a blunt instrument: it pulls on several pathways at once, which is useful for studying the system broadly but poor for isolating a single effect.

PT-141's profile shifted toward the central MC4R signaling. By isolating that pathway and dropping the pigmentation emphasis, the metabolite became the more focused compound — the tool for studying central melanocortin signaling rather than the whole family at once.

Mechanism: pigmentation vs the brain

The selectivity difference maps onto a clean mechanistic split.

Melanotan II's headline activity is at MC1R on melanocytes, driving melanin synthesis — the pigmentation effect it was built to study. PT-141's headline activity is central: MC4R agonism in hypothalamic pathways, the arousal-related circuitry that motivated its separate program. This is also what distinguishes PT-141 from the vascular sexual-health drugs (the PDE5 inhibitors) — it acts upstream and centrally on the neural signaling, not peripherally on blood flow.

So while both engage the melanocortin system, they are studied for almost opposite endpoints: one for skin-pigment biology, the other for central nervous-system signaling. The shared chemistry hides a genuine functional divergence.

The regulatory split

Few peptide pairs show as sharp a regulatory contrast.

• PT-141 has an approved pharmaceutical identity: bremelanotide was approved by the FDA under the brand Vyleesi for a specific indication. That gives it a registered status most research peptides lack — though, critically, the approved drug is not the same as research-grade PT-141 from chemical suppliers.
• Melanotan II has never been approved by the FDA or any major regulator for any human use. Health authorities in multiple countries have issued warnings about unapproved melanotan products sold outside the research context.

This is a case where a compound and its own metabolite sit on opposite sides of the regulatory line. For a researcher, it underscores that "related to an approved drug" tells you nothing about a research compound's own status — melanotan II is closely related to an approved molecule and is itself entirely unapproved.

Sourcing and the verification trap

Here the structural closeness that defines the pair becomes a sourcing hazard. Melanotan II (~1024 Da) and PT-141 (~1025 Da) have nearly identical masses and related sequences. That closeness makes substitution and mislabeling a real risk that a bare HPLC purity figure cannot catch — a high-purity chromatogram tells you the vial contains a clean cyclic peptide, not which one.

This is why mass-spec identity confirmation is essential for both, more than for most research peptides:

Marker	What to look for (both compounds)
HPLC purity	≥98% by reversed-phase HPLC, batch-specific
Mass spec	Observed mass confirming the correct compound and distinguishing the cousin
Cyclization check	Correct mass also confirms the ring actually formed
Third-party testing	Independent lab (Janoshik, MZ Biolabs, or equivalent)
Documentation	Batch-specific COA tied to your lot

A supplier publishing only a purity number, with no mass spec, has done less verification than this close structural relationship warrants. Our guide to reading a peptide COA explains how to tell a batch-specific certificate from a decorative one. You can review both compound profiles in the catalog at /peptides/melanotan-2 and /peptides/pt-141, with the full catalog at /peptides.

Bottom line

Melanotan II and PT-141 are the same chemistry's two branches: a non-selective, unapproved pigmentation-research parent, and a focused, centrally-acting metabolite with its own approved pharmaceutical identity. The selectivity gap is the heart of it — melanotan II is the broad, blunt tool; PT-141 is the targeted one — and the regulatory split is its sharpest practical consequence. Their structural closeness, finally, is what makes mass-spec identity confirmation non-negotiable for either: with masses this similar, purity alone cannot tell you which molecule is in the vial.

For a research design, match the compound to the pathway, hold the line on batch-specific HPLC plus mass-spec identity, and treat the parent-metabolite kinship as a verification requirement rather than a footnote. Compare them against the rest of the field in our research library and check any candidate supplier against our 15 vendor red flags.

For research use only. Not FDA-approved (melanotan II) / research-grade material is not the approved drug (PT-141), not for human consumption. Nothing here is a cosmetic, therapeutic, or outcome claim for either compound.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity